Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128490 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT02128490 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 189 participants.
The verdict
NCT02128490, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in gout participants with moderate renal impairment.
Interventions
- DRUG Colchicine
- DRUG Naproxen
- DRUG Febuxostat placebo
- DRUG Febuxostat IR
- DRUG Febuxostat XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02128490
The ClinicalTrials.gov registry entry for NCT02128490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Colchicine is the first listed.
NCT02128490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02128490 about?
NCT02128490 is a clinical study titled "Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment". The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in gout participants with moderate renal impairment.
What is the current status of trial NCT02128490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2014-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02128490?
The interventions under investigation include: Colchicine (DRUG), Naproxen (DRUG), Febuxostat placebo (DRUG), Febuxostat IR (DRUG), Febuxostat XR (DRUG).
Who is sponsoring clinical trial NCT02128490?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.